Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioblastoma × Valganciclovir × Clear all

Phase

Phase NA 1 Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Kaposi 3 Lymphoproliferative Disorders 3 Epstein-Barr Virus Infections 3 Multi-centric Castleman's Disease 2 Lymphoma 2 Acquired Immunodeficiency Syndrome 2 Stomach Neoplasms 1 Pyloric Stenosis, Hypertrophic 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Macular dystrophy, corneal type 1 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphadenopathy 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Immune Reconstitution Inflammatory Syndrome 1 Hodgkin Disease 1 Head and Neck Neoplasms 1 HIV Infections 1 Glioblastoma 1 EBV Lymphomas 1 Cytomegalovirus Infections 1 Castleman Disease 1 Brain Neoplasms 1

Interventions

Temozolomide 154 Bevacizumab 88 Radiotherapy 75 Radiation 23 Magnetic Resonance Spectroscopy 23 Lomustine 18 Irinotecan 18 pembrolizumab 17 Surgical Procedures, Operative 16 Carmustine 16 Erlotinib Hydrochloride 12 Nivolumab 11 Specimen Handling 10 Aminolevulinic Acid 10 sargramostim 9 Thalidomide 9 Chemotherapy, Adjuvant 9 Carboplatin 9 Immunoglobulin G 7 Filgrastim 7 Etoposide 7 Drug Therapy 7 Disulfides 7 Cilengitide 7 Sunitinib 6 Sorafenib 6 O(6)-benzylguanine 6 Cyclophosphamide 6 antineoplaston AS 2-1 5 antineoplaston A10 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04116411 2025-12-22

VIGAS2

Karolinska Institutet

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡